Clinical trial NCT03579654: Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance
Official title: A Phase 2, Randomized Study of Proscavax, a PSA/IL-2/GM-CSF Vaccine, in Treatment-naive Patients With Clinically Localized Prostate Cancer Versus an Active Surveillance Strategy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: Prostate Specific Antigen
Immunotherapy
Lead sponsor: OncBioMune Pharmaceuticals
Sponsor class: OTHER
First posted: 2018-07-06
Enrollment: 120
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients.

The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years following administration of Proscavax or active surveillance, the effect of the vaccine on prostate-specific antigen (PSA) doubling time and the assessment of adverse events in these patients.

Eligible patients in this study will include men who are 18 years and older and who have a previously untreated early stage prostate cancer regardless of the date of diagnosis.

Detailed description: This study will have 2 arms and patients will be randomized 2:1 into the Proscavax treatment arm (Arm 1) versus the active surveillance arm (Arm 2).

In study Arm 1, 6 doses of the vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.

In study Arm 2, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.

Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the prostate.
2. Age ≥ 18 years.
3. Clinically localized prostate cancer:

   * T1 (Cancer can only be seen under a microscope),
   * NX (Regional lymph nodes cannot be assessed) or N0 (Cancer cannot be seen in the lymph nodes),
   * MX (Presence of distant metastasis cannot be assessed) or M0 (Cancer hasn't spread to other parts of the body).
4. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
6. Patients must have the following laboratory values:

   1. Absolute neutrophil count (ANC) \> 1500/µL
   2. Platelet count \>100,000/µL
   3. Hemoglobin \> 10 g/dL
   4. Bilirubin \< 1.5 x upper limits of normal
   5. Aspartate aminotransferase (AST) \< 1.5 x upper limits of normal
   6. Adequate estimated glomerular filtration rate (eGFR) \> 30 mL/min per 1.73 m2 (adjusted for race)
7. Patient consent has been obtained according to local Institutional Review Board for acquisition of research specimens.
8. Patient is accessible and compliant for follow-up.
9. Prostate biopsy requirements:

   1. If diagnosis was within one year of baseline visit, participant must have at least one biopsy with at least 10 cores.
   2. If diagnosis was more than 1 year prior to baseline visit, participant must have a minimum of 2 biopsies, one of which must be within 2 years prior to baseline visit. Patients must have been diagnosed with prostate cancer within 2 years of randomization (no history of prostate adenocarcinoma in any biopsies taken more than 2 years prior to randomization).
10. Must have NCCN low or favorable-intermediate risk prostate cancer defined as:

    * \<50% of cores involved with cancer for eligibility and 50% or greater of cores involved with cancer progression. Only cores from standard TRUS biopsy (not MRI-guided cores) will be counted towards the number of cores involved.
    * No primary Gleason pattern 4 (Gleason score 4+3) disease in any cores (TRUS or MRI-guided)
    * PSA less than 20 ng/mL
    * No extracapsular extension (\<T3)
11. Patients with female partners of childbearing potential must use at least one form of Investigator-approved contraception while on-study and for 30 days after their last administration of study investigational therapy. Acceptable birth control options include:

    1. surgical sterilization (patient and/or patient's partner),
    2. approved hormonal contraceptives or therapies (such as birth control pills, Depo-Provera, or Lupron Depot),
    3. barrier methods (such as a condom or diaphragm) used with a spermicide, and
    4. an intrauterine device (IUD).

Exclusion Criteria:

1. Unwillingness or inability (such as coagulopathy) to undergo serial prostate biopsy.
2. History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for \> 5 years.
3. Evidence of metastatic prostate cancer.
4. Immune-compromised patients including but not limited to: systemic immune suppressive medications within 6 weeks of enrolling; HIV-positive and below normal cluster of differentiation 4 (CD4) lymphocytes (less than 500 cells per microliter). Patients must be tested for HIV seropositivity and CD4 lymphocyte count to be eligible for the study.
5. Inability to give consent.
6. Any condition that, according to the investigator, would make the patient an inappropriate study candidate.
7. Patients with significant cardiac disease including heart failure that meets New York Heart Association (NYHA) class II and IV definitions, history of myocardial infarction within 6 months of study entry, uncontrolled dysrhythmias.
8. Patients with existing autoimmune disorders (IL-2 and GM-CSF carry risk of exacerbating underlying autoimmune disorders).

Primary outcomes:
measure: Prostate cancer progression measured by PSA test
timeFrame: At pre-study, and then every 3 months till 2 years, starting at week 7 for both arms
measure: Prostate cancer progression measured by digital rectal examination (DRE)
timeFrame: At pre-study and then every 6-months for 2 years
measure: Prostate cancer progression measured by prostate Biopsy
timeFrame: At pre-study and then every 12-months for 2 years
Secondary outcomes:
measure: PSA doubling time
timeFrame: At pre-study, and then every 3 months till 2 years, starting at week 7 for both arms
measure: Assessment of Adverse Events
timeFrame: From first injection until 30 days past the 24-month assessments
Other outcomes:
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Harvard Medical Faculty Physicians Practice
name: Rupal S Bhatt, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: